[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610163":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":20,"responsibleParty":27,"collaborators":20,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":20,"eligibilityCriteria":35,"healthyVolunteers":31,"sex":36,"minAge":37,"maxAge":20,"enrollmentInfo":38,"targetDuration":20,"studyType":41,"phases":42,"briefSummary":44,"conditions":45,"keywords":20,"overallStatus":47,"whyStopped":20,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":20},{"fullName":5,"class":6},"University of Arkansas","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single-arm study of low-dose naltrexone (LDN)","EXPERIMENTAL","Low dose Naltrexone 3 mg is taken orally once daily to be taken with food at night. Patient will be given a pill dairy to assure compliance with the medication.",[13],"Drug: Naltrexone",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Naltrexone","Naltrexone, a structurally similar compound to the opioid antagonist naloxone, but with longer half-life and higher bioavailability, was first synthesized in the 1960s and approved by Food and Drug Administration (FDA) in 1980s for treatment of opioid addiction. Its use was later expanded for management of alcohol addiction as well. The typical dose of naltrexone used for opioid and alcohol addiction is 50-100mg \\[19\\].\n\nNaltrexone at one-tenth of the original addiction treatment dose, referred to as LDN, exhibits interesting paradoxical pharmacology and enhances endogenous opioid production. It also showed exhibiting multiple other pharmacological effects ranging from inhibition of proliferation of cancer cells, modulating immune response there by slowing the progression of autoimmune diseases and exhibiting the inhibitory effect of pro-inflammatory cytokines thereby reducing the symptoms of neuropathic and non-cancer related pain.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Aaron Holley","CONTACT","5016868274","JAHolley@uams.edu",{"type":28,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100610163","phase-2-low-dose-naltrexone-ldn-for-management-of-fatigue-in-prostate-cancer-patients-on-androgen-deprivation-therapy-adt-100610163",false,"NCT07224009","Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)","Phase II Clinical Trial Evaluating the Safety and Efficacy of Low Dose Naltrexone (LDN) for the Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)","Inclusion Criteria\n\n* Histologically or cytologically confirmed biochemical recurrence and on ADT for at least 3 months. Metastatic castrate-sensitive and castrate-resistant prostate cancer on ADT with or without novel hormonal therapy like apalutamide, darolutamide, enzalutamide and abiraterone.\n* Initiation of hormonal ablative therapy within 3 months of registration.\n* ECOG performance status \\\u003C3.\n* Patients must have normal organ and marrow function as defined below:\n\n  * leukocytes \\>3,000\u002FμL\n  * absolute neutrophil count \\>1,500\u002FμL\n  * platelets \\>100,000\u002FμL\n  * total bilirubin within normal institutional limits\n  * AST(SGOT)\u002FALT(SGPT) \\\u003C2.5 X institutional upper limit of normal\n  * creatinine ≤2.5.0\n  * left ventricular ejection fraction \\>45%\n  * FACIT-F score \\\u003C 43 on screening\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria\n\n* Prior chemotherapy received in the last three months.\n* Patients currently on PARP inhibitors.\n* Currently taking or have taken within 10 days of enrollment.\n* Patients may not be receiving any other investigational agents.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to Naltrexone or other agents used in the study.\n* History of other malignancies other than nonmelanoma skin cancer, unless in complete remission and off therapy for that disease for at least 5 years.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, history of congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Any Patient with acute hepatitis and liver failure are excluded.","MALE","18 Years",{"count":39,"type":40},60,"ESTIMATED","INTERVENTIONAL",[43],"PHASE2","The study is being done to see if a small daily dose of naltrexone (LDN, 3 mg pill) can help reduce tiredness (fatigue) in men with prostate cancer. All men in this study are being treated with hormone therapy (also called androgen deprivation therapy, or ADT). Some may also be taking newer hormone medicines such as apalutamide, daralutamide, enzalutamide, or abiraterone.",[46],"Metastatic Prostate Cancer","NOT_YET_RECRUITING","2026-06-16",{"date":50,"type":51},"2026-06-17","ACTUAL",{"date":53,"type":40},"2026-07",{"date":55,"type":40},"2029-01",{"name":5,"class":6}]